Search

Aboriginal community members throughout the Kimberley will take a lead role in driving healthy skin messages within their own communities thanks to a major funding boost to The Kids Research Institute Australia’s SToP Trial.

The Kids Research Institute Australia researchers will lead a new national clinical trial (COSI-2) to determine whether topical coconut oil can reduce late onset sepsis in extremely preterm infants.

Seven important The Kids Research Institute Australia research projects have received support from the Future Health Research and Innovation Fund through the WA Near-Miss Awards (WANMA).

Paediatric audiologist Associate Professor Chris Brennan-Jones has been announced as a finalist for the country’s leading national science awards – the Australian Museum Eureka Prizes.

World-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.

Researchers from The Kids Research Institute Australia are joining forces with international experts in acute rheumatic fever (ARF) and rheumatic heart disease (RHD) to transform the diagnosis of these diseases thanks to an $US8 million grant from the Leducq Foundation.

Young Aboriginal and Torres Strait Islander people receiving long-term, painful injections to prevent deadly complications from rheumatic heart disease (RHD) will design their own optimum treatment program thanks to latest research at The Kids Research Institute Australia.

Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.

Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive 'nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children.

Invasive Group B Streptococcus remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.